TY  - GEN 
AU  - Montero Vílchez, Trinidad
AU  - Cuenca Barrales, Carlos
AU  - Rodríguez Tejero, Andrea
AU  - Martínez López, Antonio
AU  - Arias Santiago, Salvador Antonio
AU  - Molina Leyva, Alejandro
PY  - 2022
UR  - http://hdl.handle.net/10481/73947
AB  - Adalimumab is currently the only biological medicine approved by the FDA for the treatment
of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible
due to their impact on pharmacoeconomics. However, packaging,...
LA  - eng
PB  - MDPI
KW  - Adalimumab
KW  - Biosimilar
KW  - Hidradenitis suppurativa
KW  - Switching
TI  - Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
DO  - 10.3390/jcm11041007
ER  -